We compared remission status at completion of chemotherapy with changes in MRI biomarkers obtained by advanced MRI techniques, including total tumor volume calculated from whole-body diffusion-weighted imaging and fat fraction by mDIXON soon after induction of chemotherapy for patients with multiple myeloma. The early change in fat fraction of lumbar bone marrow and serum monoclonal protein after 2 cycles of chemotherapy contributed significantly to the prediction of CR/VGPR status. Results of this study may indicate that prediction of remission status can be achieved by assessing bone marrow on lumbar spinal MRI with mDIXON.
This abstract and the presentation materials are available to members only; a login is required.